Lungenkarzinom beim alten und geriatrischen Patienten

Chapter
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Angesichts der demographischen Entwicklung der kommenden Jahrzehnte wird der Anteil der älteren Lungenkrebs-Patienten bei einem aktuellen Altersmedian von 68 Jahren weiter ansteigen. Dabei ist höheres Lebensalter grundsätzlich kein alleiniger Ausschlussgrund für eine Therapiemodalität, vielmehr müssen individuell Allgemeinzustand und Komorbiditätsstatus berücksichtigt werden. In den frühen Stadien besteht in Hinsicht auf den Therapieerfolg eine leichtgradige Überlegenheit für die Lobektomie gegenüber einer sublobären Resektion, im Falle einer funktionellen Inoperabilität steht die stereotaktische Radiotherapie als sinnvolle Alternative zur Verfügung. Patienten in lokoregionär fortgeschrittenen Stadien werden wenn möglich radio-/chemotherapiert. Bei Einschränkungen wird auf eine kurativ dosierte alleinige Radiotherapie zurückgegriffen. Im fernmetastasierten Stadium kommen Carboplatin-haltige Kombinationsschemata oder Monotherapien zur Anwendung. Hier sind im Besonderen stratifizierbare zielgerichtete Therapien bei der Detektion von prädiktiven Biomarkern zu berücksichtigen. Nicht zu vernachlässigen ist im fortgeschrittenen Stadium die frühzeitige palliativmedizinische Versorgung im Hinblick auf Symptomkontrolle und psychosozialer Begleitung.

Literatur

  1. Atagi S, Kawahara M et al (2012) Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 13:671–678CrossRefPubMedGoogle Scholar
  2. Bayman N, Alam N, Faivre-Finn C (2010) Radiotherapy for lung cancer in the elderly. Lung Cancer 68:129–136CrossRefPubMedGoogle Scholar
  3. Berry MF, Coleman BK et al (2015) Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients. Ann Surg Oncol 22:642–648CrossRefPubMedGoogle Scholar
  4. Borghaei H, Paz-Ares L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639CrossRefPubMedPubMedCentralGoogle Scholar
  5. Brahmer J, Reckamp KL et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135CrossRefPubMedPubMedCentralGoogle Scholar
  6. Bravo Iñiguez B, Armstrong KW et al (2016) Thirty-day mortality after lobectomy in elderly patients eligible for lung cancer screening. Ann Thorac Surg 101:541–546CrossRefPubMedGoogle Scholar
  7. Coate LE, Massey C et al (2011) Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. J Thorac Oncol 6:537–544CrossRefPubMedGoogle Scholar
  8. Colinet B, Jacot W et al (2005) A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson’s index. Br J Cancer 93:1098–1105CrossRefPubMedPubMedCentralGoogle Scholar
  9. Corre R, Greillier L et al (2016) Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08–02 study. J Clin Oncol 34:1476–1483CrossRefPubMedGoogle Scholar
  10. Eigentler TK, Hassel JC et al (2016) Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 45:7–18CrossRefPubMedGoogle Scholar
  11. Fores RM, Park BJ et al (2009) Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer. J Thorac Cardiovasc Surg 138:11–18CrossRefGoogle Scholar
  12. Früh M, De Ruysscher D et al (2013) Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi99–vi105CrossRefPubMedGoogle Scholar
  13. Ghaly G, Kamel M et al (2016) Video-assisted thoracoscopic surgery is a safe and effective alternative to thoracotomy for anatomical segmentectomy in patients with clinical stage I non-small cell lung cancer. Ann Thorac Surg 101:465–472CrossRefPubMedGoogle Scholar
  14. Goeckenjan G, Sitter H et al (2010) Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft. Pneumologie 64(Suppl 2):S23–S155Google Scholar
  15. Greer JA, Pirl WF et al (2012) Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol 30:394–400CrossRefPubMedGoogle Scholar
  16. Gridelli C (2001) The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly lung cancer vinorelbine Italian study. Oncologist 6(Suppl 1):4–7CrossRefPubMedGoogle Scholar
  17. Gridelli C, Perrone F et al (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362–372CrossRefPubMedGoogle Scholar
  18. Gridelli C, de Marinis F et al (2014) Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study. J Thorac Oncol 9:991–997CrossRefPubMedGoogle Scholar
  19. Grills IS, Mangona VS et al (2010) Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 28:928–935CrossRefPubMedGoogle Scholar
  20. Guckenberger M, Allgäuer M et al (2013) Safety and efficacy of stereotactic body radiotherapy for stage I non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol 8:1050–1058CrossRefPubMedGoogle Scholar
  21. Herbst RS, Baas P et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOT-010): a randomised controlled trial. Lancet 387:1540–1550CrossRefPubMedGoogle Scholar
  22. Hurria A, Togawa K et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29:3457–3465CrossRefPubMedPubMedCentralGoogle Scholar
  23. Kates M, Perez X et al (2009) Validation of a model to predict perioperative mortality from lung cancer resection in the elderly. Am J Respir Crit Care Med 179:390–395CrossRefPubMedGoogle Scholar
  24. Keedy VL, Temin S et al (2011) American society of clinical oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29:2121–2127CrossRefPubMedGoogle Scholar
  25. Landreneau RJ, Normolle DP et al (2014) Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched analysis. J Clin Oncol 32:2449–2455CrossRefPubMedPubMedCentralGoogle Scholar
  26. Malhotra J, Mhango G et al (2015) Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER-Medicare analysis. Ann Oncol 26:768–773CrossRefPubMedGoogle Scholar
  27. Nishijima TF, Muss HB et al (2016) Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. Cancer Treat Rev 45:30–37CrossRefPubMedGoogle Scholar
  28. Novello S, Barlesi F et al (2016) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines. Ann Oncol 27(Suppl 5):v1–v27CrossRefPubMedGoogle Scholar
  29. Okami J, Ito Y et al (2010) Sublobar resection provides an equivalent survival after lobectomy in elderly patients with early lung cancer. Ann Thorac Surg 90:1651–1656CrossRefPubMedGoogle Scholar
  30. Pallis AG, Gridelli C et al (2014) Management of elderly patients with NSCLC; updated expert’s opinion paper: EORTC elderly task force, lung cancer group and international society for geriatric oncology. Ann Oncol 25:1270–1283CrossRefPubMedGoogle Scholar
  31. Park S, Kim IR et al (2013) Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer. Ann Oncol 24:1630–1639CrossRefPubMedGoogle Scholar
  32. Quoix E, Zalcman G et al (2011) Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 378:1079–1088CrossRefPubMedGoogle Scholar
  33. Reck M, Rodríguez-Abreu D et al. (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833CrossRefPubMedGoogle Scholar
  34. Rittmeyer A, Barlesi F et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265CrossRefPubMedGoogle Scholar
  35. Rivera C, Falcoz PE et al (2011) Surgical management and outcomes of elderly patients with early-stage non-small cell lung cancer: a nested case–control study. Chest 140:874–880CrossRefPubMedGoogle Scholar
  36. Rossi A, Di Maio M et al (2012) Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 30:1692–1698CrossRefPubMedGoogle Scholar
  37. Rueth NM, Parsons HM et al (2012) Surgical treatment of lung cancer: predicting the postoperative morbidity in the elderly population. J Thorac Cardiovasc Surg 143:1314–1323CrossRefPubMedGoogle Scholar
  38. Shirvani SM, Jiang J et al (2014) Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg 149:1244–1253CrossRefPubMedPubMedCentralGoogle Scholar
  39. Smith CB, Kale M et al (2014) Comparative outcomes of elderly stage I lung cancer patients treated with segmentectomy via video-assisted thoracoscopic surgery versus open resection. J Thorac Oncol 9:383–389CrossRefPubMedGoogle Scholar
  40. Soria JC, Brisgard D, Le Chevallier T (2001) Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol 12:1667–1670CrossRefPubMedGoogle Scholar
  41. Soria JC, Felip E et al (2015) Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomized controlled phase 3 trial. Lancet Oncol 16:897–907CrossRefPubMedGoogle Scholar
  42. Tamiya M, Tamiya A et al (2016) A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer. Med Oncol 33:2.  https://doi.org/10.1007/s12032-015-0715-7CrossRefPubMedGoogle Scholar
  43. Temel JS, Greer JA et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742CrossRefPubMedGoogle Scholar
  44. Vansteenkiste J, Crinò L et al (2014) 2nd ESMO consensus conference on lung cancer: early-stage non-small cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 25:1462–1474CrossRefPubMedGoogle Scholar
  45. Wanders R, Steevens J et al (2011) Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: a prospective population-based study. Eur J Cancer 47:2691–2697CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Internistische Onkologie der ThoraxtumorenThoraxklinik am Universitätsklinikum HeidelbergHeidelbergDeutschland

Section editors and affiliations

  • Nicolai Härtel
    • 1
  1. 1.Interdisziplinäres TumorzentrumUniversitätsmedizin MannheimMannheimDeutschland

Personalised recommendations